Obinutuzumab-Tolerant CD20 Cancer Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
CD20-positive cancers often become tolerant to obinutuzumab treatment, leading to reduced effectiveness and recurrence, necessitating a combination therapy to enhance treatment outcomes.
Innovation Solution
Combining type II anti-CD20 antibodies, such as obinutuzumab, with compounds like prednisolone, doxorubicin, and their salts or prodrugs to increase treatment efficacy in obinutuzumab-tolerant CD20-positive cancers, particularly B-cell non-Hodgkin's lymphoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If obinutuzumab treatment is used alone, then initial treatment effectiveness is achieved, but cancer tolerance develops leading to reduced effectiveness and recurrence
Solution Approach 1:
The patent combines obinutuzumab (a type II anti-CD20 antibody) with specific chemotherapy compounds (prednisolone, doxorubicin, vincristine, or their salts/prodrugs) to create a combination therapy regimen. This merging of immunotherapy with chemotherapy mechanisms addresses cancer tolerance by attacking through multiple pathways simultaneously, preventing the development of resistance that occurs with monotherapy.
2Reliability
If combination therapy with multiple compounds is used, then treatment effectiveness against tolerant cancer is enhanced, but treatment complexity increases
Solution Approach 1:
The patent specifies precise administration parameters for the combination therapy, including dosage ranges, administration schedules, and sequential timing of different compounds. By optimizing these parameters, the treatment achieves enhanced effectiveness against obinutuzumab-tolerant cancer while managing complexity through standardized protocols. The invention provides specific guidance on administering prednisolone, doxorubicin, or vincristine in combination with obinutuzumab to maximize therapeutic benefit.
Data Source
AI summary
There are cases of CD20-positive cancer where the cancer is tolerant to obinutuzumab and cases where the cancer recurs after an obinutuzumab-containing treatment.For CD20-positive cancer that is tolerant to obinutuzumab or CD20-positive cancer that has recurred following an obinutuzumab-containing treatment, a type II anti-CD20 antibody is used in combination with one or more compounds selected from the group consisting of prednisolone, doxorubicin, vincristine, and salts and prodrugs thereof. Among these compounds, prednisolone, doxorubicin, and salts and prodrugs thereof may be selected. Furthermore, among these compounds, prednisolone or a salt or prodrug thereof may be selected.